INO vs. CERS, NGM, KNTE, FGEN, CDMO, CVAC, NVAX, INVA, CDXC, and RAPT
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Cerus (CERS), NGM Biopharmaceuticals (NGM), Kinnate Biopharma (KNTE), FibroGen (FGEN), Avid Bioservices (CDMO), CureVac (CVAC), Novavax (NVAX), Innoviva (INVA), ChromaDex (CDXC), and RAPT Therapeutics (RAPT). These companies are all part of the "medical" sector.
Cerus (NASDAQ:CERS) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Cerus has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
Cerus has higher revenue and earnings than Inovio Pharmaceuticals. Cerus is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
78.4% of Cerus shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 7.1% of Cerus shares are held by company insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Cerus had 10 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 14 mentions for Cerus and 4 mentions for Inovio Pharmaceuticals. Cerus' average media sentiment score of 0.61 beat Inovio Pharmaceuticals' score of 0.04 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.
Cerus has a net margin of -19.27% compared to Cerus' net margin of -16,238.91%. Inovio Pharmaceuticals' return on equity of -58.65% beat Cerus' return on equity.
Inovio Pharmaceuticals received 148 more outperform votes than Cerus when rated by MarketBeat users. However, 72.26% of users gave Cerus an outperform vote while only 71.46% of users gave Inovio Pharmaceuticals an outperform vote.
Cerus presently has a consensus target price of $3.83, indicating a potential upside of 118.11%. Inovio Pharmaceuticals has a consensus target price of $96.00, indicating a potential upside of 712.18%. Given Cerus' higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Cerus.
Summary
Cerus beats Inovio Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
